Evotec is a global leader in drug discovery and development, offering extensive CRO and CDMO services across all stages of the R&D continuum, from target identification to the clinic, delivering efficient, high-quality, and cost-effective solutions.

We integrate deep disease understanding, a multimodality approach, advanced technologies and tailored solutions to enhance the probability of success. Our innovative and flexible approach supports collaboration through standalone CRO/CDMO services, integrated drug discovery and development programs, or strategic partnerships, regardless of your stage in the discovery-development journey.

Expertise in Modalities and Therapeutic Areas
Our broad capabilities cover small molecules, antibodies, antibody drug conjugates, oligonucleotides, peptides, cell therapy, RNA-targeted therapies and other advanced modalities. With particular strength in pharmacology, toxicology, and preclinical formulation, we help de-risk development and optimize the selection of therapeutic candidates. Our consultative approach ensures partners benefit from our deep expertise in complex disease areas, enabling better outcomes from early discovery to clinical development.

Innovative R&D Platforms
Our AI-powered proprietary R&D platforms, including PanOmics and iPSC technologies, integrate advanced analytics and automation to enhance disease understanding and ensure human relevance. By leveraging continuous manufacturing and high-throughput platforms, we provide faster, more reliable access to high-quality drug candidates, reducing time to clinic and enabling data-driven decision-making.

Global Presence and Flexibility
Evotec operates globally with an expansive R&D infrastructure, allowing us to offer flexibility in partnering models and scalability in operations. Our state-of-the-art facilities and diverse scientific team of over 4,000 experts are equipped to handle the most complex challenges across therapeutic areas and modalities, including biologics, small molecules, and cell therapies.